
Michael D Decker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7664105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. New England Journal of Medicine, 2014, 371, 635-645.	13.9	636
2	Psychoactive Drugs and the Risk of Injurious Motor Vehicle Crashes in Elderly Drivers. American Journal of Epidemiology, 1992, 136, 873-883.	1.6	381
3	Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. Journal of Pediatrics, 1992, 120, 184-189.	0.9	235
4	Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the Literature. Clinical Infectious Diseases, 2008, 46, 402-412.	2.9	219
5	Central Venous Catheter Infections. Pediatric Clinics of North America, 1988, 35, 579-612.	0.9	166
6	International variation in the management of infants hospitalized with respiratory syncytial virus. European Journal of Pediatrics, 1998, 157, 215-220.	1.3	164
7	ACUTE RESPIRATORY DISEASE HOSPITALIZATIONS AS A MEASURE OF IMPACT OF EPIDEMIC INFLUENZA. American Journal of Epidemiology, 1985, 122, 468-476.	1.6	145
8	Immune Responses in Infants Whose Mothers Received Tdap Vaccine During Pregnancy. Pediatric Infectious Disease Journal, 2013, 32, 1257-1260.	1.1	131
9	Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States. Vaccine Journal, 2004, 11, 1045-1053.	2.6	118
10	Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine, 2013, 31, 770-776.	1.7	102
11	Seroepidemiology of Hepatitis B in Tennessee Prisoners. Journal of Infectious Diseases, 1984, 150, 450-459.	1.9	90
12	How Soon After a Prior Tetanus-Diphtheria Vaccination Can One Give Adult Formulation Tetanus-Diphtheria-Acellular Pertussis Vaccine?. Pediatric Infectious Disease Journal, 2006, 25, 195-200.	1.1	82
13	Incidence of Pertussis Infection in Healthcare Workers. Infection Control and Hospital Epidemiology, 1999, 20, 120-123.	1.0	77
14	Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal, 1994, 13, 206-211.	1.1	74
15	Acellular Pertussis Vaccines for Infants. New England Journal of Medicine, 1996, 334, 391-392.	13.9	73
16	Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatric Infectious Disease Journal, 2001, 20, S10-S18.	1.1	71
17	A Randomized Clinical Trial of Acellular Pertussis Vaccines in Healthy Adults: Doseâ€Response Comparisons of 5 Vaccines and Implications for Booster Immunization. Journal of Infectious Diseases, 1999, 180, 397-403.	1.9	65
18	Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology, 2005, 65, 1964-1966.	1.5	63

#	Article	IF	CITATIONS
19	The Use and Efficacy of Child Restraint Devices. JAMA - Journal of the American Medical Association, 1984, 252, 2571.	3.8	61
20	Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. Journal of Pediatrics, 1992, 121, 523-527.	0.9	61
21	Strengthening the Supply of Routinely Recommended Vaccines in the United States. JAMA - Journal of the American Medical Association, 2003, 290, 3122.	3.8	57
22	Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents. Pediatric Infectious Disease Journal, 2010, 29, 391-396.	1.1	51
23	Medications and the Safety of the Older Driver: Is There a Basis for Concern?. Human Factors, 1992, 34, 33-47.	2.1	47
24	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	1.7	47
25	Fluzone® High-Dose Influenza Vaccine. Expert Review of Vaccines, 2016, 15, 1495-1505.	2.0	45
26	Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants. Pediatric Infectious Disease Journal, 2010, 29, 105-110.	1.1	44
27	Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age. Pediatric Infectious Disease Journal, 2014, 33, 630-636.	1.1	42
28	Combination vaccines. Pediatric Infectious Disease Journal, 1994, 13, 345-347.	1.1	38
29	Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatric Infectious Disease Journal, 1994, 13, 635-639.	1.1	38
30	Immunogenicity and Safety of 1 vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus. Journal of Pediatrics, 2012, 161, 676-681.e2.	0.9	38
31	ACELLULAR PERTUSSIS VACCINES. Pediatric Clinics of North America, 2000, 47, 309-335.	0.9	37
32	Endocarditis and Infections of Intravascular Devices Due to Eikenella corrodens. American Journal of the Medical Sciences, 1986, 292, 209-212.	0.4	36
33	Trivalent Inactivated Influenza Virus Vaccine Given to Two-Month-Old Children. Pediatric Infectious Disease Journal, 2009, 28, 1099-1104.	1.1	36
34	Cellular Immunity in Adolescents and Adults following Acellular Pertussis Vaccine Administration. Vaccine Journal, 2007, 14, 288-292.	3.2	34
35	Combination vaccines consisting of acellular pertussis vaccines. Pediatric Infectious Disease Journal, 1997, 16, S97-S102.	1.1	34
36	The Incidence of Hepatitis B in Tennessee Prisoners. Journal of Infectious Diseases, 1985, 152, 214-217.	1.9	33

#	Article	IF	CITATIONS
37	Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children. Pediatric Infectious Disease Journal, 2012, 31, 47-52.	1.1	32
38	Pertussis vaccines. , 2013, , 447-492.		32
39	Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatric Infectious Disease Journal, 1998, 17, S113-S116.	1.1	31
40	Prevalence of Antibody toBordetella pertussisAntigens in Serum Specimens Obtained from 1793 Adolescents and Adults. Clinical Infectious Diseases, 2004, 39, 1715-1718.	2.9	30
41	Lack of consistent relationship between quantity of aluminum in diphtheria–tetanus–acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine, 2002, 20, S44-S47.	1.7	29
42	Humoral immunity 10†years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine, 2018, 36, 2282-2287.	1.7	29
43	Prevalence of Positive Serology for Acute <i>Chlamydia pneumoniae</i> Infection in Emergency Department Patients with Persistent Cough. Academic Emergency Medicine, 1997, 4, 179-183.	0.8	25
44	Prospective Assessment of the Effect of Needle Length and Injection Site on the Risk of Local Reactions to the Fifth Diphtheria-Tetanus-Acellular Pertussis Vaccination. Pediatrics, 2008, 121, e646-e652.	1.0	25
45	Kinetics of Pertussis Immune Responses to Tetanusâ€Diphtheriaâ€Acellular Pertussis Vaccine in Health Care Personnel: Implications for Outbreak Control. Clinical Infectious Diseases, 2009, 49, 584-587.	2.9	25
46	Pertussis (Whooping Cough). Journal of Infectious Diseases, 2021, 224, S310-S320.	1.9	25
47	Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. Journal of Pediatrics, 1993, 122, 410-413.	0.9	23
48	An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Vaccine, 1999, 17, 2999-3006.	1.7	23
49	Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine, 2016, 34, 4172-4179.	1.7	23
50	Case Report: Cat Scratch Disease: An Infection Beyond the Lymph Node. American Journal of the Medical Sciences, 1986, 292, 389-390.	0.4	22
51	VALIDITY OF FOOD CONSUMPTION HISTORIES IN A FOODBORNE OUTBREAK INVESTIGATION. American Journal of Epidemiology, 1986, 124, 859-863.	1.6	21
52	Combination vaccines: Problems and promise. Journal of Pediatrics, 2000, 137, 291-295.	0.9	21
53	Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine, 2010, 28, 1451-1453.	1.7	21
54	lssues in Design of Clinical Trials of Combination Vaccines. Annals of the New York Academy of Sciences, 1995, 754, 234-240.	1.8	20

#	Article	IF	CITATIONS
55	Highly differentiated human airway epithelial cells: a model to study host cell–parasite interactions in pertussis. Infectious Diseases, 2016, 48, 177-188.	1.4	20
56	Pertussis Vaccines. , 2018, , 711-761.e16.		20
5 7	Eikenella corrodens. Infection Control, 1986, 7, 36-41.	0.5	18
58	Pertussis seroprevalence in emergency department staff. Annals of Emergency Medicine, 1994, 24, 413-417.	0.3	18
59	Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine, 2020, 38, 7323-7330.	1.7	18
60	Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine, 2021, 39, 5541-5547.	1.7	18
61	Pertussis vaccines. , 2008, , 467-517.		18
62	Who should receive hepatitis A vaccine?. Pediatric Infectious Disease Journal, 1995, 14, 258-260.	1.1	17
63	Combination Vaccines. Infectious Disease Clinics of North America, 2001, 15, 209-230.	1.9	17
64	Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 105-114.	0.6	17
65	Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal, 1991, 10, 315-318.	1.1	16
66	Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine, 2016, 34, 5273-5278.	1.7	16
67	The Detection of Penicillin-Resistant Pneumococci: The Compliance of Hospital Laboratories with Recommended Methods. American Journal of Clinical Pathology, 1985, 84, 357-360.	0.4	13
68	Description of Case-Mix Adjusters by the Severity of Illness Working Group of The Society of Hospital Epidemiologists of America (SHEA). Infection Control and Hospital Epidemiology, 1988, 9, 309-316.	1.0	13
69	Methodological Issues With the Risk of Relapse Study in Patients With Multiple Sclerosis After Yellow Fever Vaccination. Archives of Neurology, 2012, 69, 144.	4.9	12
70	Challenges for Licensure of New Diphtheria, Tetanus Toxoid, Acellular Pertussis (DTaP) Combination Vaccines: Counterpoint. Pediatric Infectious Disease Journal, 1996, 15, 1070-1073.	1.1	11
71	Reactogenicity of Tetanus, Diphtheria, 5-Component Acellular Pertussis Vaccine Administered as a Sixth Consecutive Acellular Pertussis Vaccine Dose to Adolescents. Pediatric Infectious Disease Journal, 2010, 29, 1067-1071.	1.1	10
72	Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth. Journal of the Pediatric Infectious Diseases Society, 2017, 6, e69-e74.	0.6	10

#	Article	IF	CITATIONS
73	Combination Vaccines. , 2018, , 198-227.e13.		10
74	Association of self-reported injury and alcohol consumption in medical outpatients. Journal of General Internal Medicine, 1990, 5, 486-489.	1.3	9
75	Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65Ây of age and older. Human Vaccines and Immunotherapeutics, 2017, 13, 2058-2064.	1.4	8
76	Combination vaccines. , 2013, , 981-1007.		7
77	Case Report: Fatal Pulmonary Toxoplasmosis Following Chemotherapy. American Journal of the Medical Sciences, 1991, 302, 152-154.	0.4	6
78	Letter to the Editor. Vaccine, 2004, 22, 2681-2684.	1.7	6
79	Combination vaccines. , 2008, , 1069-1101.		6
80	The Development of Indicators. Infection Control and Hospital Epidemiology, 1991, 12, 490-492.	1.0	6
81	Estimating the Effectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine. Journal of Infectious Diseases, 2015, 211, 497-498.	1.9	5
82	Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical Centers. Clinical Infectious Diseases, 2015, 61, 1344-1345.	2.9	5
83	Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP. Vaccine, 2019, 37, 5003-5008.	1.7	5
84	Combination vaccines. Primary Care - Clinics in Office Practice, 2001, 28, 739-761.	0.7	4
85	Safety and Immunogenicity of Tetanus-Diphtheria-Acellular Pertussis Vaccine Administered to Children 10 or 11 Years of Age. Vaccine Journal, 2014, 21, 1560-1564.	3.2	4
86	Gonococcal perihepatitis in a female adolescent. Fitz-Hugh-Curtis syndrome. JAMA - Journal of the American Medical Association, 1978, 239, 339-340.	3.8	4
87	Brand-specific rates of pertussis disease among Wisconsin children given 1–4 doses of pertussis Vaccine, 2010–2014. Vaccine, 2020, 38, 7063-7069.	1.7	3
88	One Confirmed and 2 Suspected Cases of Heartland Virus Disease. Clinical Infectious Diseases, 2020, 71, 3237-3240.	2.9	3
89	THE USE AND EFFICACY OF CHILD RESTRAINT DEVICES. American Journal of Public Health, 2009, 99, 1160-1160.	1.5	2
90	Intravenous Therapy: Expanding the Bounds of Safety. JAMA - Journal of the American Medical Association, 1987, 258, 2418.	3.8	1

#	Article	IF	CITATIONS
91	Change and Constancy, 2002. Infection Control and Hospital Epidemiology, 2002, 23, 10-10.	1.0	1
92	Reply: Recurrent Broviac Catheter Infections. Journal of Infectious Diseases, 1988, 157, 214-214.	1.9	0
93	MANAGEMENT OF CATHETER-RELATED BACTEREMIA. Pediatric Infectious Disease Journal, 1988, 7, 303.	1.1	Ο
94	Motor Vehicle Fatalities and the Minimum Drinking Age-Reply. JAMA - Journal of the American Medical Association, 1989, 261, 3411.	3.8	0
95	Role of Pertactin in Pertussis Vaccines: The Jury Is Still Out. Journal of Infectious Diseases, 2004, 189, 1332-1333.	1.9	Ο
96	Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals, 2005, 33, 59.	0.5	0
97	Issues for Health Practitioners in the Use of Combination Vaccines. , 1999, , 249-267.		0
98	The breast cancer controversy. JAMA - Journal of the American Medical Association, 1977, 238, 2141-2142.	3.8	0